News | October 01, 2025
Miels will formally assume the role on January 1, 2026
Sanofi Ventures drives innovation through leading and participating in private financing rounds for pioneering healthcare companies
Expanded capabilities that continue to push the boundaries of innovation—advancing drug delivery solutions for patients, customers, and consumers around the world
82,514 sq ft facility to host up to 15 biotech companies, fueling the development of next-generation medicines
BIL also holds an option to increase its equity stake by an additional 15%
Ultra-high purity surfactant for biologics and parenteral drug formulations
Alkem's Pertuza is an affordable, indigenously-developed and manufactured biosimilar of pertuzumab
No post-injection Delirium/Sedation Syndrome (PDSS) observed through 56 weeks
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
